Human Genome Epidemiology Literature Finder
|
Records 1 - 4 (of 4 Records) |
| Query Trace: Weight Gain and CYP2C9[original query] |
|---|
| Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes research and clinical practice 2006 May 72 (2): 148-54. Suzuki Kazuko, Yanagawa Tatsuo, Shibasaki Toshiaki, Kaniwa Nahoko, Hasegawa Ryuichi, Tohkin Masahi |
| The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review. Frontiers in genetics 2021 7 12 675053. Baye Assefa M, Fanta Teferi G, Siddiqui Moneeza K, Dawed Adem |
| Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study. BMC medicine 2022 7 20 (1): 261. Ricardo-Silgado Maria L, Singh Sneha, Cifuentes Lizeth, Decker Paul A, Gonzalez-Izundegui Daniel, Moyer Ann M, Hurtado Maria D, Camilleri Michael, Bielinski Suzette J, Acosta Andr |
| The role of candidate pharmacogenetic variants in determining valproic acid efficacy, toxicity and concentrations in patients with epilepsy. Frontiers in pharmacology 2024 11 15 1483723. Hady Yazbeck, Joe Youssef, Wassim Nasreddine, Abdullah El Kurdi, Nathalie Zgheib, Ahmad Beydo |
- Page last reviewed:Feb 1, 2024
- Content source:

